{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T23:31:48Z","timestamp":1769038308883,"version":"3.49.0"},"reference-count":25,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancers. Given its low incidence, male breast cancer (MBC) remains understudied; this 33-year Serbian cohort was assessed for clinicopathological features, therapeutic approaches, genetic alterations, and survival. Methods: We retrospectively analyzed MBC patients diagnosed between 1991 and 2024 at the Institute for Oncology and Radiology of Serbia. Data included demographics, tumor characteristics, and stage, treatment, hormone receptor and HER2 status, Ki-67 index, genetic testing, and survival. Results: A total of 191 patients were identified (median age 66). Family history was negative in 91% and positive in 5.8%. T2 tumors were most frequent (36%), and 96% presented without metastasis. Mastectomy with axillary or sentinel lymph node dissection was performed in 78.5%. Neoadjuvant chemotherapy and radiotherapy were administered in 5.8% and 8.4%. Estrogen receptor positivity was 72%, progesterone receptor 88%, HER2 overexpression 11.0%, and triple-negative tumors 2.6% (40% with axillary involvement). High Ki-67 (\u226515%) was recorded in 28.8%. Adjuvant chemotherapy, radiotherapy, and hormone therapy were given in 36%, 58%, and 68%. Among 37 genetically tested patients, seven had pathogenic variants (BRCA1, BRCA2, CHEK2, PALB2). Disease recurrence occurred in 30%. Median follow-up was 53 months. Median disease-free survival (DFS) was 82 months (1-, 2-, 5-, 10-year DFS: 87%, 73%, 57%, 39%). Median overall survival (OS) 131 months (1-, 2-, 5-, 10-year OS: 95%, 93%, 73%, 53%). Conclusions: This long-term cohort highlights the predominance of hormone-receptor positivity, the infrequency of germline mutations, and moderate survival rates, informing patient management and guiding future studies.<\/jats:p>","DOI":"10.3390\/cancers18020326","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:48:08Z","timestamp":1768985288000},"page":"326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Male Breast Cancer in Serbia: A 33-Year Retrospective Cohort Study of Genetic Predisposition, Clinicopathological Features, and Survival Outcomes"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-891X","authenticated-orcid":false,"given":"Zorka","family":"Ini\u0107","sequence":"first","affiliation":[{"name":"Clinic of Surgical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-541X","authenticated-orcid":false,"given":"Milan","family":"\u017degarac","sequence":"additional","affiliation":[{"name":"Clinic of Surgical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1698-6981","authenticated-orcid":false,"given":"Ana","family":"Krivoku\u0107a","sequence":"additional","affiliation":[{"name":"Department for Genetic Counseling, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1891-1677","authenticated-orcid":false,"given":"Ognjen","family":"\u017divkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-1250","authenticated-orcid":false,"given":"Marko","family":"Buta","sequence":"additional","affiliation":[{"name":"Clinic of Surgical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3183-9058","authenticated-orcid":false,"given":"Nikola","family":"Vu\u010di\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Surgical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-7044","authenticated-orcid":false,"given":"Dobrica","family":"Stevi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Surgical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5392-5062","authenticated-orcid":false,"given":"An\u0111ela","family":"Mili\u0107evi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Markovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Surgical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Suboti\u0107a 8, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"\u0110uri\u0161i\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Surgical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/BCTT.S516124","article-title":"Male Breast Cancer: Evaluating the Current Landscape of Diagnosis and Treatment","volume":"17","author":"Agelidis","year":"2025","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Melan, K., Loap, P., and Kirova, Y. (2025). Current Perspectives on Non-Metastatic Male Breast Cancer: Genetics, Biology, and Treatment Advances: A Systematic Review. Cancers, 17.","DOI":"10.3390\/cancers17193270"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101311","DOI":"10.1016\/j.esmoop.2023.101311","article-title":"88P Male breast cancer: A rare conundrum","volume":"8","author":"Muddabhaktuni","year":"2023","journal-title":"ESMO Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of Male Breast Cancer: ASCO Guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1734049","DOI":"10.1155\/2022\/1734049","article-title":"Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment","volume":"2022","author":"Zheng","year":"2022","journal-title":"J. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.21037\/gs-2025-10","article-title":"Global and regional trends in male breast cancer burden: A comparative analysis of incidence, prevalence, mortality, and disability-adjusted life years in China and worldwide (1990\u20132021)","volume":"14","author":"Zou","year":"2025","journal-title":"Gland Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13690-024-01404-3","article-title":"Global, regional, and national trends in the burden of breast cancer among individuals aged 70 years and older from 1990 to 2021: An analysis based on the global burden of disease study 2021","volume":"82","author":"Liu","year":"2024","journal-title":"Arch. Public Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103027","DOI":"10.1016\/j.eclinm.2024.103027","article-title":"Global, regional, and national burden of male breast cancer in 204 countries and territories: A systematic analysis from the global burden of disease study, 1990\u20132021","volume":"80","author":"Li","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ionescu, S., Nicolescu, A.C., Marincas, M., Madge, O.L., and Simion, L. (2022). An Update on the General Features of Breast Cancer in Male Patients\u2014A Literature Review. Diagnostics, 12.","DOI":"10.20944\/preprints202205.0328.v1"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ferrucci, M., Milardi, F., Passeri, D., Pozzerle, M., Cagol, M., Saibene, T., Michieletto, S., Toffanin, M., Del Bianco, P., and Marchet, A. (2025). Quality-of-Life and Oncological Outcomes in Male Breast Cancer: Insights from an Extensive 20-Year Experience. Cancers, 17.","DOI":"10.3390\/cancers17050829"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4274\/ejbh.galenos.2022.2022-5-2","article-title":"Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients","volume":"18","author":"Aydin","year":"2022","journal-title":"Eur. J. Breast Health"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kaur, A., Buragohain, P.D., Talukdar, A., Roy, P.S., Mohinta, Z., and Malhotra, M. (2025). Male Breast Cancer: Clinicopathological Characteristics of the Patients Treated in a Tertiary Care Centre in Northeast India. Indian J. Surg., 1\u20138.","DOI":"10.1007\/s12262-025-04336-6"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda, E., Anchondo-Nu\u00f1ez, P., Acu\u00f1a-Aguilar, L.E., G\u00f3mez-Valles, F.O., and Ram\u00edrez-Valdespino, C.A. (2022). Subtypes of Breast Cancer, NIH. Exon Publications.","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13058-024-01872-z","article-title":"Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes","volume":"26","author":"Nandu","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zelli, V., Silvestri, V., Valentini, V., Bucalo, A., Rizzolo, P., Zanna, I., Bianchi, S., Coppa, A., Giannini, G., and Cortesi, L. (2021). Transcriptome of male breast cancer matched with germline profiling reveals novel molecular subtypes with possible clinical relevance. Cancers, 13.","DOI":"10.3390\/cancers13184515"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: Insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1200\/JCO.19.02190","article-title":"Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women with Breast Cancer","volume":"38","author":"Yadav","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jamaoncol.2023.7194","article-title":"Mortality Risks Over 20 Years in Men with Stage I to III Hormone Receptor\u2013Positive Breast Cancer","volume":"10","author":"Leone","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.20312","article-title":"Breast carcinoma in men: A population-based study","volume":"101","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.62713\/aic.3888","article-title":"18 Years Experience of an Italian Breast Unit Among Male Breast Cancer: A Retrospective Observational Study","volume":"96","author":"Taraschi","year":"2025","journal-title":"Ann. Ital. Chir."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103057","DOI":"10.1016\/j.jogoh.2025.103057","article-title":"Male breast cancer: Insights from a two-center epidemiological analysis","volume":"55","author":"Charpentier","year":"2026","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_22","first-page":"524","article-title":"Male breast cancer: A multicenter study in Aragon over 27 years","volume":"102","year":"2024","journal-title":"Cirug\u00eda Espa\u00f1ola (Engl. Ed.)"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.21873\/anticanres.17497","article-title":"Male Breast Cancer: A Single Institutional Clinicopathological Profiling","volume":"45","author":"Banerjee","year":"2025","journal-title":"Anticancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000501542","article-title":"Living with Male Breast Cancer: A Qualitative Study of Men\u2019s Experiences and Care Needs","volume":"15","author":"Nguyen","year":"2020","journal-title":"Breast Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11912-023-01489-z","article-title":"Male Breast Cancer: A Review on Diagnosis, Treatment, and Survivorship","volume":"26","author":"Bhardwaj","year":"2024","journal-title":"Curr. Oncol. Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:55:33Z","timestamp":1768985733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020326"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020326","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}